Taysha (NASDAQ: TSHA) CFO gets RSUs and 231,000 options award grant

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. reported that its Chief Financial Officer, Kamran Alam, received new equity awards. On January 12, 2026 he was granted 359,000 shares of common stock in the form of restricted stock units, which will vest in four equal annual installments beginning on January 12, 2027, as long as he remains in continuous service.

On the same date, he also received an employee stock option to buy 231,000 shares of common stock at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the rest vesting in 36 equal monthly installments, subject to continued service. After these awards, he beneficially owned 1,546,603 shares of common stock directly and 231,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alam Kamran

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, STE 1430

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		A		359,000(1)	A	$0	1,546,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.86	01/12/2026		A		231,000		(2)	01/12/2036	Common Stock	231,000	$0	231,000	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

2. 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Kamran Alam, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Taysha (TSHA) CFO Kamran Alam receive?

On January 12, 2026, CFO Kamran Alam received a grant of 359,000 restricted stock units (RSUs) of Taysha Gene Therapies common stock and an employee stock option for 231,000 shares with an exercise price of $4.86 per share.

How do the 359,000 RSUs granted to the TSHA CFO vest?

The 359,000 RSUs vest in four equal annual installments starting on January 12, 2027. Each installment requires the CFO’s continuous service through the applicable vesting date.

What are the vesting terms of the 231,000 stock options granted to the TSHA CFO?

For the 231,000 stock options with a $4.86 exercise price, 25% of the underlying shares vest and become exercisable on January 12, 2027. The remaining 75% vest and become exercisable in 36 equal monthly installments thereafter, subject to continued service.

How many Taysha (TSHA) shares does the CFO own after these grants?

After the reported grants, the CFO beneficially owned 1,546,603 shares of common stock directly, and also held 231,000 employee stock options directly.

Were the TSHA CFO’s new equity awards reported as direct or indirect ownership?

Both the 359,000 RSUs (reported as common stock) and the 231,000 employee stock options were reported as direct (D) beneficial ownership by the CFO.

Is this TSHA Form 4 about a purchase or a compensation grant?

The Form 4 reports equity compensation grants to the CFO: a restricted stock unit award and an employee stock option grant, rather than open-market purchases or sales.